Lilly's retatrutide outshines Ozempic on weight loss, blood sugar control in trial

What happened

Eli Lilly said its experimental obesity drug retatrutide beat Novo Nordisk's Ozempic on blood sugar control and delivered more than double the weight loss in a diabetes trial. Retatrutide lowered A1C by 2.2% versus 1.8% for Ozempic.

Confirmed

Global impact / market context

Stronger trial results make retatrutide a likely driver of Lilly's next growth wave after Zepbound and Mounjaro, which means the company could win more prescriptions and defend its position in the fast-growing obesity drug market against Novo Nordisk.

Analyst inference

The obesity drug market is a competition between Lilly and Novo Nordisk over share of a rapidly growing patient pool. Retatrutide's edge suggests Lilly may extend its lead, which can shape investor expectations for future revenue and capital spending.

Analyst inference

What to watch

1. The late-stage trial compared 9 mg and 12 mg doses of retatrutide with a 2 mg dose of Ozempic, the highest approved dose, over 80 weeks. Confirmed
2. Watch whether Lilly files retatrutide for regulatory approval and how regulators assess its triple-hormone mechanism, which means it targets GLP-1, GIP and glucagon receptors. Proposed
3. Track whether retatrutide's larger weight loss and blood sugar reductions translate into doctor prescriptions, insurer coverage and pricing decisions that affect Lilly's revenue. Analyst inference

Evidence

• Original source link unavailable